- Home
- JUNS vs CING Comparison
JUNS vs CING Comparison
Compare JUNS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- CING
- Stock Information
- Founded
- JUNS 2015
- CING 2012
- Country
- JUNS United States
- CING United States
- Employees
- JUNS N/A
- CING N/A
- Industry
- JUNS
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- JUNS
- CING Health Care
- Exchange
- JUNS NYSE
- CING Nasdaq
- Market Cap
- JUNS 17.6M
- CING 16.2M
- IPO Year
- JUNS 2024
- CING 2021
- Fundamental
- Price
- JUNS $0.62
- CING $4.01
- Analyst Decision
- JUNS
- CING Strong Buy
- Analyst Count
- JUNS 0
- CING 4
- Target Price
- JUNS N/A
- CING $30.67
- AVG Volume (30 Days)
- JUNS 101.5K
- CING 101.1K
- Earning Date
- JUNS 05-20-2025
- CING 05-08-2025
- Dividend Yield
- JUNS N/A
- CING N/A
- EPS Growth
- JUNS N/A
- CING N/A
- EPS
- JUNS N/A
- CING N/A
- Revenue
- JUNS N/A
- CING N/A
- Revenue This Year
- JUNS N/A
- CING N/A
- Revenue Next Year
- JUNS N/A
- CING N/A
- P/E Ratio
- JUNS N/A
- CING N/A
- Revenue Growth
- JUNS N/A
- CING N/A
- 52 Week Low
- JUNS $0.51
- CING $1.80
- 52 Week High
- JUNS $19.51
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- CING 46.43
- Support Level
- JUNS N/A
- CING $3.90
- Resistance Level
- JUNS N/A
- CING $4.41
- Average True Range (ATR)
- JUNS 0.00
- CING 0.26
- MACD
- JUNS 0.00
- CING -0.03
- Stochastic Oscillator
- JUNS 0.00
- CING 33.77
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.